Wörner W, Pfleiderer S, Rietbrock N
Abteilung für Klinische Pharmakologie, Johann-Wolfgang-Goethe-Universität Frankfurt am Main, Germany.
Int J Clin Pharmacol Ther Toxicol. 1993 May;31(5):218-22.
Serum proteins are non-enzymatically glycosylated dependent on the concentration of free glucose and measurements of their concentration are used to control diabetic carbohydrate metabolism. Eight patients with insulin-dependent diabetes mellitus (IDDM) and 8 patients with non-insulin-dependent diabetes mellitus (NIDDM) with glycosylated hemoglobin levels of at least 10.5% were studied during a 6-week period of antidiabetic therapy. Glycosylated serum albumin (GSA) and glycosylated total serum proteins (GSP) were measured weekly using an affinity chromatography procedure. The fructosamine test (FA) and the measurement of mean blood glucose (MBG) were also carried out weekly. Glycosylated hemoglobin and its glucose adduct HbA1c were determined at 14-day intervals (HPLC-method). All measured parameters decreased during the period of the study. The correlation coefficients for the glycosylated proteins versus the MBG determined one week earlier were highest for GSA [IDDM: r(GSA/MBG-1) = 0.726, p < 0.001 for the single values and 0.984, p < 0.001 for the mean values; NIDDM: r (GSA/MBG-1) = 0.636, p < 0.001 for the single values and 0.986, p < 0.001 for the mean values]. The differences between the IDDM and NIDDM group probably occurred because 6 NIDDM patients were taking glibenclamide (7.0-10.5 mg/day) which is known to inhibit the glycosylation reaction of albumin. The fructosamine test is more prone to interferences than the selective determination of GSA. GSA determination therefore, gives precise data in medium term diabetic control.
血清蛋白会非酶糖基化,这取决于游离葡萄糖的浓度,并且其浓度的测量可用于控制糖尿病患者的碳水化合物代谢。在为期6周的抗糖尿病治疗期间,对8例糖化血红蛋白水平至少为10.5%的胰岛素依赖型糖尿病(IDDM)患者和8例非胰岛素依赖型糖尿病(NIDDM)患者进行了研究。每周使用亲和色谱法测量糖化血清白蛋白(GSA)和糖化总血清蛋白(GSP)。每周还进行果糖胺试验(FA)和平均血糖(MBG)测量。每隔14天(采用高效液相色谱法)测定糖化血红蛋白及其葡萄糖加合物HbA1c。在研究期间,所有测量参数均下降。对于GSA,糖化蛋白与提前一周测定的MBG之间的相关系数最高[IDDM:r(GSA/MBG - 1)= 0.726,单个值p < 0.001,平均值r = 0.984,p < 0.001;NIDDM:r(GSA/MBG - 1)= 0.636,单个值p < 0.001,平均值r = 0.986,p < 0.001]。IDDM组和NIDDM组之间的差异可能是因为6例NIDDM患者正在服用格列本脲(7.0 - 10.5毫克/天),已知该药物会抑制白蛋白的糖基化反应。果糖胺试验比选择性测定GSA更容易受到干扰。因此,测定GSA能为中期糖尿病控制提供精确数据。